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Objectives. To study the effect of the 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA)-reductase inhibitor atorvastatin
on the potential mechanisms involved in the recruitment of
monocytic cells into the vessel wall.
Background. Inhibitors of HMG-CoA-reductase reduce cardio-
vascular mortality though the mechanisms yet elucidated. Most
ischemic events are secondary to disruption of atherosclerotic
plaques highly infiltrated by macrophages.
Methods. Atherosclerosis was induced in the femoral arteries of
rabbits by endothelial damage and atherogenic diet for 4 weeks.
Then, animals were switched to standard chow and randomized to
receive either no treatment or atorvastatin (5 mg/kg/d) and killed
after 4 weeks.
Results. Atorvastatin induced a significant reduction in serum
lipids and in lesion size. Arterial macrophage infiltration was
abolished by the treatment, and monocyte chemoattractant
protein-1 (MCP-1) was significantly diminished in the neointima
and in the media. Nuclear factor kappa-B (NF-kB) was activated
in the 60% of the lesions, both in macrophages and vascular
smooth muscle cells (VSMC), of the untreated group while only in
30% of the atorvastatin group. NF-kB activity was also lower in
the uninjured aorta and liver of treated compared with untreated
rabbits. In cultured VSMC, MCP-1 expression and NF-kB activity
induced by tumor necrosis factor alpha were downregulated by
atorvastatin.
Conclusions. In a rabbit atherosclerosis model, atorvastatin
diminishes the neointimal inflammation, and this could contrib-
ute to the stabilization of the atherosclerotic plaque. This may be
an additional explanation for the reduction of acute ischemic
events in patients treated with statins.
(J Am Coll Cardiol 1998;32:2057–64)
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Cholesterol-lowering drugs slow the progression of coronary
atherosclerosis and diminish the incidence of ischemic events
(1). Moreover, the inhibitors of the 3-hydroxy-3-methyl-
glutaryl-coenzyme A (HMG-CoA)-reductase also reduce total
and coronary mortality, both in secondary and in primary
prevention (2,3).
Acute ischemic events are mainly secondary to plaque
disruption and thrombosis. Although it is well known that
lipid-rich plaques are more prone to rupture, the mechanisms
by which HMG-CoA-reductase inhibitors reduce coronary
events are not completely understood. Macrophage infiltration
has been related to unstable coronary syndromes, probably
because these cells secrete proteolytic enzymes, which weaken
the cap of the lesion (4,5). As a consequence, the study of the
mechanisms leading to the accumulation of macrophages
within the lesions is reaching increasing interest. Monocyte
chemoattractant protein-1 (MCP-1) is the best studied attract-
ant for monocytes, and its presence in the neointima has been
demonstrated in several experimental models and in humans
(6). Nuclear factor kappa-B (NF-kB) is the main nuclear factor
involved in the activation of its transcription (7), and we have
recently shown that this factor was activated in the damaged
arteries in a model of atherosclerosis in rabbits (8).
The purpose of this study was to determine the effect of the
HMG-CoA-reductase inhibitor atorvastatin on the neointimal
content of macrophages, the presence of MCP-1 and the
NF-kB activation in an experimental model of atherosclerosis
in rabbits. In addition we explored whether atorvastatin could
modulate in a direct manner these factors in cultured VSMC.
Methods
In Vivo Study. Design. Twenty-five New Zealand male
rabbits weighing 3.5–4 kg (mean 3.4 6 0.6 kg) were used (Fig.
1). The animals were housed in individual cages and quaran-
tined for 7 days before use, and were treated according to the
Fundacio´n Jime´nez-Dı´az’s policies guidelines for animal care.
Atherosclerosis was induced in each femoral artery by endo-
thelial desiccation with nitrogen, as previously described (9),
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followed by 4 weeks of atherogenic diet (0.5% cholesterol and
14% coconut oil diet) (Mucedola, Italy). After that, a control
angiography was performed to discard those animals with a
complete occlusion of the artery, and they were switched to
standard chow and randomized to receive 5 mg/kg/d of ator-
vastatin (Parke-Davis, Ann Arbor, MI) (n 5 7) or no treatment
(n 5 9). The dose of atorvastatin was chosen on the basis of
previous experiments designed to test the effect of the drug (1,
2, 5 and 10 mg/kg/day) on chow consumption. The control of
the drug intake was done daily and the dietary regime con-
sisted of feeding 50 g of standard chow the first week, 100 g the
second week and 150 g the last 2 weeks. After 4 weeks all
animals were killed. In Figure 1, a scheme of the experimental
protocol is shown. Five control animals fed standard chow and
with no experimental intervention were also studied.
Angiography. Animals were anesthetized and given antibi-
otics. After the medial laparotomy, the abdominal aorta was
reached and exposed. A ligature was placed to control the
bleeding, and then it was cannulated and nitroglycerin was
infused to avoid spasm. After 1 min, and under microscope,
2 mL of contrast (Sodium Ioxaglato, Hexabris 320; ROVI S.A.,
Madrid, Spain) was infused. Hemostasis was achieved by local
pressure and the wound was closed. Four animals with an
occluded artery were excluded from the study.
Sample collection. Animals were anesthetized and both
femoral arteries and the aorta were exposed. One of the
femoral arteries and a piece of the aorta were removed, the
adventitial layer was carefully peeled off and immediately
snap-frozen in liquid nitrogen. The animals were killed with an
overdose of pentobarbital (Abbot, Madrid, Spain) and a liver
sample was obtained and frozen. The other femoral artery was
cannulated, fixed in situ with 4% buffered formaldehyde at
100 mm Hg pressure, removed and embedded in paraffin.
Plasma samples were collected 24 h postmeal at the beginning
of the study, at the moment of randomization and at death.
Plasma cholesterol, LDL and HDL cholesterol and triglycer-
ides were measured by enzymatic techniques (bioMe´rieux,
Lyon, France).
Morphometric analysis. The morphometric analysis was
performed on orcein-stained arterial sections with the
NewSketch 1212 graphic tablet (Genius, Ontario, Canada)
linked to a microcomputer using the autoCAD 10.0 software.
Sections with the maximal lesion were chosen for quantifica-
tion.
Immunohistochemistry. Paraffin-embedded arteries were
cross-sectioned into 4-mm-thick pieces at 5-mm intervals from
the proximal to the distal end, dewaxed and rehydrated.
Macrophages and MCP-1 were identified according to previ-
ously described techniques (8).
For quantification, the sections with the maximal lesion in
each animal were chosen. Computer-assisted morphometric
analysis was performed with the Cue-2 semiautomatic image
analysis system (Olympus, Hamburg, Germany). The arterial
cross-sections stained with the antibodies were digitized via an
Olympus microscope (BH-2) connected to a CCD video
camera. The labeled areas in the intima and the media were
delimited, and after image enhancement and segmentation
(transformation to a binary image) a grey value ranging from 0
to 255 was assigned to each pixel and automatic analysis was
performed. Results were expressed as immunostained area.
Southwestern histochemistry. This method was developed
to detect the distribution and DNA-binding activity of
NF-kB in situ using a digoxigenin-labeled double-stranded
DNA probe with a specific consensus sequence that binds to
NF-kB, according to a previously described technique with
modifications (10). The synthetic sense (59-AGTTGA-
GGGGACTTTCCCAGGC-39) and antisense (59-GCCTGG-
GAAAGTCCCCTCAACT-39) probes (Genosys Biotechnology,
London, UK) were annealed by heating at 80°C for 2 min. The
probes were labeled with digoxigenin (DIG oligonucleotide
39-end labeling; Boehringer Mannheim, Mannheim, Germa-
ny). Arterial sections were dewaxed, rehydrated, incubated
Abbreviations and Acronyms
AP-1 5 activated protein-1
G3PDH 5 glyceraldehyde 3-phosphate dehydrogenase
HMG-CoA 5 3-hydroxy-3-methyl-glutaryl-coenzyme A
MCP-1 5 monocyte chemoattractant protein-1
NF-kB 5 Nuclear factor kappa-B
TNFa 5 tumor necrosis factor alpha
VSMC 5 vascular smooth muscle cells
Figure 1. Scheme of the experimental protocol.
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with 5 mmol/L levamisole for 30 min and fixed with 0.2%
paraformaldehyde. They were then digested with 0.5% pepsin
in 1N HCl for 30 min, washed with HEPES and incubated with
0.1 mg/mL DNAse I for 30 min and washed again with HEPES
buffer. The DNA-binding reaction was performed by incuba-
tion with 100 pmol/mL of the labeled DNA probe overnight at
37°C, and then the preparations were washed with HEPES
buffer, washing buffer (0.3% Tween 20 in: 0.1 mol/L maleic
acid, 0.15 mol/L NaCl, pH 7.5) and blocking solution (0.1 3
SSC, 0.1% SDS diluted 1:10 in washing buffer) for 1 h.
Preparations were incubated with an anti–digoxigenin anti-
body conjugated with alkaline phosphatase (Boehringer Mann-
heim), and color reaction was developed. Sections were mounted
with glycerol. Preparations without probe were used as a negative
control, and to test the specificity of the technique, a mutant
NF-kB probe was used (59-AGTTGAGGCTCCTTT-
CCCAGGC-39). For the simultaneous detection of NF-kB and
macrophages or VSMC, before mounting the sections, they were
washed with phosphate-buffered solution (PBS) and immunohis-
tochemistry was done according to the above-described technique
for macrophages. The detection of VSMC was done with an
anti-alpha-actin (HHF35; ENZO Diagnostic, New York, New
York) in the same conditions as for macrophages.
Electrophoretic mobility shift assays. Tissue and nuclear
protein extraction was done with modifications as previously
described (8). Protein concentration was quantified by the
BCA method (Pierce, Rockford, IL). Gel shift assays were
performed with a commercial kit according to the instructions
of the manufacturer (Promega, Madison, WI). NF-kB (59-
AGTTGAGGGGACTTTCCCAGGC-39) and AP-1 (59-
CGCTTGATGAGTCAGCCGGAA-39) consensus oligonu-
cleotides were [32P] end-labeled by incubation for 10 min at
37°C with 10 U T4 polynucleotide kinase (Promega) and
10 mCi [g-32P]ATP (3000 Ci/mmol) (Amersham, Buckingham-
shire, United Kingdom).
In Vitro Studies. Cell culture. Rat thoracic aortic VSMC
were isolated and cultured as previously described (8) and
characterized by positive alpha-actin staining. VSMC were
growth-arrested by incubation in 0.5% fetal calf serum (FCS)
medium for 48 h, and then incubated with 100 U/mL TNFa
(Immugenex). Atorvastatin (1027 mol/L) (Sodium salt) was
added to the culture medium 1 h before the stimulation.
RNA extraction and Northern blot analysis. RNA was ob-
tained by the acid guanidine-thiocyanate-phenol-chloroform
method (11) and quantified by absorbance at 260 nm in
duplicate. Northern blot analysis was performed as described
elsewhere (8). The cDNA probes for human MCP-1 and
G3PDH, used as internal control, were obtained from the
American Type Culture Collection, Bethesda, Maryland. Films
were scanned using the Image Quant densitometer (Molecular
Dynamics, Sunnyvale, California).
Statistical Analysis. Results are expressed as mean 6 SD.
Lipid values and morphometric analysis were compared by
means of the Mann-Whitney U test. The macrophage infiltra-
tion was expressed as percentage and compared by the Fisher
exact test. The areas immunostained positive for MCP-1 in the
intima and the media of the vessel wall in treated and
nontreated animales were analyzed by a Kruskal-Wallis test
followed by Dunn’s multiple comparison test. Significance was
established with GraphPAD InStat (GraphPAD Software) and
differences were considered significant when p , 0.05 (two-
tailed).
Results
Weight and plasma lipids evolution. The weight of the
animals was controlled weekly to adjust the dose of drug.
Atorvastatin treatment did not modify weight evolution (no
treatment: 3.21 6 0.75 kg vs. atorvastatin: 3.37 6 0.72 kg).
After 4 weeks on the atherogenic diet, total plasma cholesterol
and LDL cholesterol raised about 20-fold over the initial
values (from 54 6 43 to 1000 6 419 and from 42 6 63 to 907 6
445 mg/dL, respectively; p , 0.004), the triglycerides around
twofold (from 63 6 18 to 133 6 78 mg/dL; p , 0.004) while the
HDL cholesterol was not modified (from 25 6 16 to 27 6 12).
When compared with the untreated animals at death, the
atorvastatin group showed significantly lower levels of plasma
cholesterol (249 6 322 vs. 595 6 404 mg/dL; p , 0.04), LDL
(48 6 27 vs. 79 6 29 mg/dL; p , 0.02) and triglycerides (51 6
33 vs. 96 6 28 mg/dL; p , 0.02). HDL cholesterol was not
modified with the treatment (25 6 7 vs. 25 6 9).
Analysis of the vascular lesions. The lesions were evalu-
ated on histological preparations stained with orcein (Fig 2,
top). The mean lesion size in each group was calculated from
those preparations showing the maximal lesion in each animal.
Maximal stenosis of the femoral arteries of the atorvastatin
group was significantly lower than that of the untreated group,
estimated both as intima/media ratio (0.129 6 0.038 vs.
0.412 6 0.322; p 5 0.001) or as a percentage of the luminal
area occupied by the lesion (10.06 6 7.03% vs. 21.24 6
13.54%; p 5 0.038) (Fig. 2, bottom).
Evaluation of the presence of macrophages in the lesions.
Macrophages were present in the neointima of the arteries of
five out of the nine animals with no treatment (56%) and in
none (0%) of the seven animals treated with atorvastatin (p 5
0.034). The mean neointimal area occupied by macrophages
was 1470 6 2750 mm2 in the untreated group. Macrophages
were also present in the media of three out of the nine
untreated animals (33%) but in none of those treated with
atorvastatin (Fig. 3).
Evaluation of MCP-1 protein expression in the lesions.
MCP-1 was evaluated by immunohistochemistry (Fig. 4, top).
All animals in the untreated group showed staining for MCP-1
(100%) versus five out of seven in the atorvastatin group
(71%). The mean area stained for MCP-1 was significantly
lower in the atorvastatin compared with the untreated group,
both in the neointima (3881 6 3898 vs. 41,657 6 43,141 mm2;
p , 0.01) and in the media (1027 6 902 vs. 16,584 6 15,401 mm2,
p , 0.05) (Fig. 4, bottom). No control animal showed any
staining.
Macrophages and MCP-1 were colocalized in the neoin-
tima, although MCP-1 seems to be present also in the medial
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layer and in areas of the neointima without macrophages,
suggesting that VSMC could be responsible for its synthesis.
The diminution in the area occupied by MCP-1 in the neoin-
tima can not be explained solely by the overall reduction in the
lesion size, since MCP-1 decreased by 90% while the lesion was
only reduced by 50%–60%.
NF-kB activation in the lesions. NF-kB activation was
studied by Southwestern histochemistry to determine the pres-
ence and localization of activated NF-kB in situ. The amount
of stained nuclei in the tissue was calculated according to a
semiquantitative score ranging from 0 to 5. We found NF-kB
activity in the neointima and media in four out of seven
animals studied in the untreated group (all $2), while only in
two out of seven in the atorvastatin treated (only one .2) and
in none of the controls. Atorvastatin treatment induced a mean
reduction of 60% in the neointimal activation and 65% in the
media. The binding of the labeled probe was specific since no
staining was found when the mutant NF-kB oligonucleotide
was used in untreated animals (Fig. 5). By double staining with
the digoxigenin-labeled oligonucleotide and an antimacro-
phages and anti-alpha-actin antibodies, we found that both cell
types were activated in the lesions (Fig. 5E and F, respectively).
However, due to the larger amount of VSMC, it seems that
their contribution is much greater than that of macrophages.
NF-kB activation in the aorta and liver. Since atherogenic
diet by itself has been shown to induce NF-kB activation in the
liver (12), we also studied by gel shift assay whether this factor
was activated in the liver and aorta. NF-kB was more activated
in the liver (Fig. 6, top) and aorta (bottom) of untreated
animals than of the atorvastatin group. Competition assays
with cold NF-kB, but not with an unrelated cold oligonucleo-
tide (AP-1), abolished the appearance of the labeled complex,
indicating the specificity of the interaction. We also studied the
activation of another transcription factor (AP-1), involved
mainly in the regulation of extracellular matrix and metallo-
proteinase genes, in the liver and aorta of the rabbits. AP-1
activity was increased in both organs of untreated rabbits, but
the treatment with atorvastatin did not induce any change in its
activation (Fig. 6). The assay was specific, as demonstrated by
the competition of the binding with cold AP-1, but not with
cold NF-kB.
Modulation of NF-kB activation and MCP-1 expression by
atorvastatin in VSMC. To establish whether the observed
atorvastatin effect on MCP-1 and NF-kB could be, at least in
part, due to a direct effect of the drug on the VSMC, we
Figure 2. Analysis of the vascular lesions. Top, Photomicrographs of
representative orcein-stained arterial sections of femoral arteries. A
greater neointimal formation (arrows) can be observed in the un-
treated (A) than in the atorvastatin treated rabbit (B). M, medial layer
(magnification 3100). Bottom, The atorvastatin-treated group had less
severe stenoses estimated both as intima/media ratio (solid bars) or as
a percentage of the luminal area occupied by the lesion (open bars).
Data are the mean 6 SD of seven treated and nine untreated rabbits.
*p 5 0.001 vs. untreated; **p 5 0.038 vs. untreated.
Figure 3. Macrophage detection by immunohistochemistry in arterial
sections. Photomicrographs of arterial sections stained with RAM11
antibody, specific for rabbit macrophages. A representative section of
each treatment group is shown. A, Nontreated group. B, Atorvastatin-
treated group. None of the control animals showed any stain (not
shown). Arrow, presence of macrophages (brown) (magnification
3400).
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studied the expression and activation of these factors induced
by tumor necrosis factor alpha (TNFa) in VSMC. TNFa
(100 U/mL) induced a sevenfold increase of MCP-1 mRNA.
Preincubation of the cells with 1027 mol/L atorvastatin for 1 h
reduced the MCP-1 expression (Fig. 7). NF-kB activation was
also induced by 100 U/mL TNFa (7.5-fold; p , 0.03) and the
preincubation of the cells with 1027 mol/L atorvastatin for 1 h
significantly diminished this activation (60%, p , 0.05).
Discussion
In the present work we have demonstrated that in a rabbit
model of atherosclerosis the-HMG-CoA-reductase inhibitor
atorvastatin reduces the inflammatory component in the ath-
erosclerotic lesion. This effect could help to explain the
reduction in ischemic events observed upon statin treatment in
clinical trials.
Inflammation and lesion stabilization. It is well demon-
strated that statins reduce the size and the extent of the lesions.
This is, however, not a convincing explanation for the reduc-
tion of the acute ischemic events that they achieve, since it is
well known that these events are usually due to the rupture of
unstable plaques independently of their size (4). In our model,
treatment with atorvastatin resulted in less severe lesions, but
also in the abolition of macrophage infiltration and in the
reduction of MCP-1. It must be emphasized that atorvastatin
treatment was not started at the beginning of the experiment
but after 4 weeks of hyperlipemic diet, in an attempt to imitate
the conditions of human atherosclerosis, where statins are used
in most cases once atherogenesis has begun.
Most thromboses of vessels with atherosclerotic lesions are
preceded by a fissure that allows the lipid core to contact the
circulating blood (13,14). An inflammatory reaction plays an
important role in this rupture, and the presence of macro-
phages in the surroundings of the fissured plaques from
patients with acute coronary syndromes has also been demon-
strated (4,5). These cells can release proteolytic enzymes that
degrade the fibrotic cap of the lesion, making it prone to
rupture (15). The presence of macrophages in the lesion is
favored by chemoattractants such as oxidized low density
lipoprotein (ox-LDL) and MCP-1. In this sense, the lipid-
lowering effect of atorvastatin would not only reduce the
generation of ox-LDL but also the synthesis of MCP-1. This
chemokine is present in human atherosclerotic lesions, mainly
in the areas infiltrated by macrophages (6,16).
In spite of the absence of macrophages in the lesions of
atorvastatin-treated rabbits, a certain amount of MCP-1 was
expressed, suggesting that the drug may modulate additional
mechanisms involved in the neointima infiltration, such as the
expression of adhesion molecules and other chemokines. In
this sense, it is noteworthy that the genes of many chemokines,
adhesion molecules and other inflammation-related proteins
possess NF-kB recognition sites in their promoters (17), and
thus the reduction of NF-kB activation achieved with the
treatment could be a pivotal point controlling different param-
eters related to inflammation within the plaque.
Mechanisms of the reduction of vascular inflammation by
atorvastatin. MCP-1 reduction by the treatment seemed to be
related to a diminution in NF-kB activity, and this effect seems
to be specific on NF-kB since the activation of AP-1, another
transcription factor commonly overexpressed during inflam-
mation and also related to vascular injury (18), was not
modified. NF-kB is responsible for the induction of MCP-1
transcription after stimulation by lipopolysaccharide (LPS),
interleukin 1-beta, TNFa and phorbol esters (7). It has been
recently shown that Lovastatin possesses a certain antioxidant
action (19), and it would therefore be interesting to study
whether this effect is related to the inhibition of NF-kB activity.
NF-kB activity was greater in the aorta and liver of un-
treated animals, that is, in tissues exposed only to hypercho-
lesterolemia without local injury, suggesting a role for circu-
lating cholesterol. This is in accordance with the results of Liao
et al. (20) and provides a link between hyperlipidemia and
plaque rupture. However, we cannot exclude the possibility
that atorvastatin also had a direct effect on the atherosclerotic
Figure 4. MCP-1 detection by immunohistochemistry in arterial sec-
tions. Top, Photomicrographs of arterial sections stained with an
anti–MCP-1 antibody. Both the neointima and the media showed
staining for MCP-1. A representative section of an untreated animal is
shown in A and of an atorvastatin treated rabbit in B. Control arteries
showed no staining for MCP-1 (not shown) (magnification 3400).
Bottom, Closed bars represent the mean area stained for MCP-1 in the
untreated animals and open bars the mean area stained in treated
animals. Data are the mean 6 SD of seven treated and nine untreated
rabbits. *p , 0.01 vs. untreated and **p , 0.05.
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lesions, since the HMG-CoA reductase is present in every cell
as an integral enzyme of the cholesterol synthesis route (21).
Because to this, other authors have shown that lovastatin
reduces neointimal formation in a model of normocholester-
olemic rabbits (22). To test this hypothesis, we carried out in
vitro experiments on atorvastatin effect on MCP-1 expression
and NF-kB activation induced in VSMC by TNFa, which is
usually present during vascular injury (23), thus excluding the
possibility of actions mediated by cholesterol reduction. In
these experiments we found that atorvastatin reduced both
MCP-1 expression and NF-kB activity, suggesting that part of
the in vivo effects of atorvastatin could be due to a direct effect
of the drug on the atherosclerotic plaques. However, the
present study was not designed to investigate the importance
of the direct effect of atorvastatin on the vessel wall. Further-
more, clinical evidence has shown consistently that lowering
cholesterol reduces the incidence of acute ischemic events not
only when achieved by statins, but also when other cholesterol-
lowering drugs (24) or even nonpharmacological approaches
are used (25). Thus, it seems wise to speculate that cholesterol
reduction was probably the main responsible of the effects seen
in our in vivo experiment, although a direct action of atorva-
statin could also play a role in these effects.
Study limitations. This study has been carried out in an
experimental model of accelerated atherosclerosis that differs
from the chronic lesions observed in human disease. However,
our findings strongly agree with observations made in human
atherosclerosis in the sense that statins reduce the incidence of
Figure 5. NF-kB activity in the lesions. NF-kB activity was determined
by Southwestern histochemistry in untreated (A), atorvastatin treated
(B) and control (C) animals. The binding of the labeled probe is
specific since no staining is found with the mutant oligonucleotide (D)
(magnification 3400). A detail of the localization of the NF-kB activity
by double staining with anti–macrophage antibody is shown in E and
with anti-alpha-actin in F (magnification 31000). The arrows indicate
the presence of a nuclei stained for NF-kB (blue) and surrounded by
a cytoplasm (brown) stained with the antibody specific for macro-
phages (E) and for VSMC (F).
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acute coronary syndromes and that inflammation plays a role
in the pathophysiology of these syndromes. Finally, it must be
noticed that we have not tested the incidence of plaque rupture
in the animals, but only the presence of cells and mediators
related to inflammation. Unfortunately, there is no animal
model in which spontaneous plaque rupture occurs. Neverthe-
less, the strong relation found in humans between inflamma-
tory cells and plaque thrombosis supports the use of macro-
phage infiltration as a marker of plaque unstability.
Conclusions. As a whole, our results demonstrate that
atorvastatin reduces the inflammatory features in the neoin-
tima and suggest a potential explanation for the reduction of
ischemic events observed with HMG-CoA-reductase inhibitors
in clinical trials. They also indicate that a part of this effect
could be due to a direct action of this drug on the atheroscle-
rotic lesions, although further work is needed to evaluate its
contribution.
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mobility shift assay (EMSA). Cellular extracts ob-
tained from the aorta and liver of the animals from
the same group were pooled. (1) positive control
with Hela nuclear extracts and (2) negative control
without cellular extract. Representative of two exper-
iments done.
Figure 7. Atorvastatin modulation of NF-kB activity and MCP-1
expression in VSMC. Vascular smooth muscle cells were growth-
arrested by serum deprivation for 48 h and then preincubated with
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